INmune Bio Inc. To Present New Biomarker And Feasibility Data From Phase 1b Study Supporting Use Of XPro To Treat Alzheimer's Disease At Clinical Trials On Alzheimer's Disease Conference Oct. 24-27
Portfolio Pulse from Benzinga Newsdesk
INmune Bio Inc. will present new biomarker and feasibility data from its Phase 1b study, supporting the use of XPro in treating Alzheimer's disease, at the Clinical Trials on Alzheimer's Disease Conference from October 24-27.
October 17, 2023 | 12:01 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
INmune Bio's presentation of new data supporting the use of XPro for Alzheimer's treatment could potentially boost investor confidence and the company's stock price.
The presentation of positive data from a Phase 1b study is a significant milestone in drug development. This news could increase investor confidence in INmune Bio's ability to bring XPro to market, potentially leading to an increase in the company's stock price.
CONFIDENCE 75
IMPORTANCE 80
RELEVANCE 100